Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
The melanocortin 1 receptor (MC1R or alpha melanocytestimulating hormone receptor) is a key protein regulating skin and hair pigmentation. Melanin synthesis is largely modulated by the agonistic ...
Clinical Trials Arena on MSN3d
Palatin’s UC therapy prompts clinical remission in a third of patientsA third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
The team then designed an astatine-211(211 At)-labeled α-melanocyte-stimulating hormone (α-MSH) peptide analog called [211 At ...
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...
Other target genes included MC1R (melanocortin 1 receptor), which regulates melanin production, in order to produce mice with golden hair rather than the usual dark fur and a variant associated ...
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin Technologies’ melanocortin-1 receptor (MC1R) agonist, PL8177. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback